Humacyte (NASDAQ:HUMA) Given Buy Rating at Benchmark

Benchmark reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report report published on Tuesday morning, Benzinga reports. Benchmark currently has a $15.00 price objective on the stock.

A number of other research firms also recently issued reports on HUMA. Piper Sandler reissued a neutral rating and set a $4.00 price target on shares of Humacyte in a research report on Tuesday, March 26th. Cantor Fitzgerald reiterated an overweight rating and set a $7.00 target price on shares of Humacyte in a report on Monday, April 1st.

Humacyte Trading Down 4.8 %

HUMA stock opened at $5.11 on Tuesday. Humacyte has a 12 month low of $1.96 and a 12 month high of $9.97. The firm’s 50-day moving average is $5.95 and its 200 day moving average is $4.22. The company has a market capitalization of $608.50 million, a PE ratio of -5.11 and a beta of 1.52. The company has a debt-to-equity ratio of 0.61, a current ratio of 8.37 and a quick ratio of 8.37.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Friday, May 10th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). On average, research analysts anticipate that Humacyte will post -0.95 EPS for the current year.

Insider Buying and Selling

In related news, Director Gordon M. Binder bought 50,000 shares of the business’s stock in a transaction on Wednesday, May 15th. The shares were bought at an average price of $6.78 per share, for a total transaction of $339,000.00. Following the completion of the purchase, the director now directly owns 160,000 shares of the company’s stock, valued at $1,084,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Humacyte news, CEO Laura E. Niklason sold 809,786 shares of the stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $7.91, for a total value of $6,405,407.26. Following the completion of the sale, the chief executive officer now directly owns 5,381,354 shares in the company, valued at $42,566,510.14. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Gordon M. Binder purchased 50,000 shares of the stock in a transaction on Wednesday, May 15th. The stock was acquired at an average cost of $6.78 per share, with a total value of $339,000.00. Following the acquisition, the director now owns 160,000 shares of the company’s stock, valued at approximately $1,084,800. The disclosure for this purchase can be found here. In the last three months, insiders purchased 54,412 shares of company stock worth $369,107 and sold 1,628,820 shares worth $12,464,121. 23.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Humacyte

Several hedge funds and other institutional investors have recently modified their holdings of HUMA. SG Americas Securities LLC increased its stake in Humacyte by 52.8% during the 4th quarter. SG Americas Securities LLC now owns 16,340 shares of the company’s stock valued at $46,000 after purchasing an additional 5,645 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Humacyte by 261.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company’s stock worth $26,000 after acquiring an additional 6,504 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Humacyte by 65.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company’s stock worth $62,000 after acquiring an additional 7,897 shares during the last quarter. Powell Investment Advisors LLC grew its stake in Humacyte by 75.0% during the 4th quarter. Powell Investment Advisors LLC now owns 21,000 shares of the company’s stock valued at $60,000 after purchasing an additional 9,000 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. purchased a new position in shares of Humacyte in the fourth quarter worth about $28,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.